PrEP for HIV Prevention: Effectiveness, Types & Key Considerations
Pre-exposure prophylaxis (PrEP) is a biomedical intervention where HIV-negative individuals take antiretroviral medication to prevent HIV acquisition. When taken consistently, PrEP reduces HIV risk by up to 99% for sexual transmission and ≥74% for injection drug use. It is a cornerstone of ending the HIV epidemic.
Types of PrEP
- Oral Daily PrEP:
- TDF/FTC (Truvada®, generics): Approved 2012. All genders, all exposure routes. Renal/bone monitoring needed.
- TAF/FTC (Descovy®): Approved 2019. MSM and transgender women only (not studied in cisgender women for vaginal exposure). Less renal/bone toxicity.
- On-Demand (2-1-1) PrEP: TDF/FTC only: 2 pills 2–24h before sex, 1 pill 24h later, 1 pill 24h after that. Only for MSM (studied in IPERGAY, ANRS IPERGAY). Not for women or people with HBV (flare risk).
- Long-Acting Injectable PrEP:
- Cabotegravir (Apretude®): 600 mg IM every 2 months (after 2 initiation doses 1 month apart). Approved 2021 for adults/adolescents ≥35 kg at risk sexually. HPTN 083 (MSM/TGW): 66% more effective than daily TDF/FTC. HPTN 084 (cisgender women): 89% more effective. No renal/bone concerns. Requires clinic visits.
Factors Influencing Effectiveness
- Adherence (the #1 factor): Daily PrEP requires ≥4 doses/week for women (cervicovaginal tissue), ≥2 doses/week for MSM (rectal tissue). Missed doses = lost protection. Injectable eliminates adherence gap.
- Partner's viral load: PrEP + partner's ART (U=U) = near-zero risk. Synergistic protection.
- Concurrent STIs: STIs (especially HSV-2, syphilis, gonorrhea, chlamydia) and bacterial vaginosis increase HIV susceptibility 2–5x. Regular STI screening/treatment enhances PrEP effectiveness.
- Drug interactions: Rare for TDF/FTC/TAF; monitor with CAB (rifampin, certain antiseizure meds reduce levels).
- Renal/hepatic function: TDF contraindicated if eGFR <60; TAF/CAB preferred. Monitor eGFR q6mo on TDF.
- Pregnancy/breastfeeding: TDF/FTC safe; TAF/CAB insufficient data.
- Substance use: Methamphetamine, alcohol associated with lower adherence. Integrate SUD care.
Monitoring on PrEP
- HIV test (4th-gen Ag/Ab or NAT) every 3 months (oral), or at each injection visit (CAB).
- Renal function (eGFR) at baseline, 3 mo, then q6mo (TDF); baseline only (TAF/CAB).
- STI screening (3-site: pharyngeal, rectal, urethral/vaginal) q3–6mo.
- Pregnancy test if applicable.
- Hepatitis B status (TDF/FTC/TAF treat HBV; stopping can cause flare).
PrEP is safe, highly effective, and available in multiple formulations to fit diverse lives. It is a powerful tool for sexual health autonomy. Talk to a provider about which option is right for you.
HIV & AIDS - Related Articles
- Where to Get Free Condoms: Comprehensive Access Guide
- HIV Transmission Facts: Debunking the Coughing and Sneezing Myth
- HIV Survival in Shower Drains: Why Environmental Transmission Is Impossible
- Protease: Understanding Its Role in Digestion & Health
- Affordable HIV Medication Options: Resources for Uninsured Patients
- HIV Testing: Understanding Routine Lab Tests & CDC Recommendations
- Understanding and Preventing HIV: Essential Precautions
